Skip to main content

Table 1 Cancer chemoresistance related miRNAs

From: Role of non-coding RNAs and RNA modifiers in cancer therapy resistance

CancersmiRNAsDrugsTargets/MechanismsReferences
Breast cancermiR-5195-3pPaclitaxelTargeting EIF4A2[83]
miR-542-3pPaclitaxelSuppressing survivin[84]
miR-181cDoxorubicinInactivating OPN;
Enhancing p-53-dependent transactivation and apoptosis
[85]
miR-381DoxorubicinDownregulating MAPK/FYN signaling[86]
CisplatinTargeting MDR1[87]
miR-100CisplatinSuppressing HAX-1;
Modulating mitochondrial apoptosis pathway
[88]
Hepatocellular carcinomamiR-19a-3pSorafenibModulating PTEN/Akt pathway[89]
miR-142-3pSorafenibTargeting ATG5 and ATG16L1[90]
miR-3129-5pDoxorubicinEnforcing mRNA stability of ZEB1[91]
miR-760DoxorubicinIncreasing PTEN expression;
Decreasing the phosphorylation of Akt
[92]
miR-21-5pCisplatinDownregulating FASLG[93]
miR-16PaclitaxelTargeting IKBKB/NF-kB signaling pathway[94]
Lung cancermiR-219a-5pCisplatinNegatively regulating FGF9[95]
miR-539CisplatinTargeting on DCLK1[96]
miR-181bCisplatinInactivating Notch2/Hes1 pathway[97]
miR-9CisplatinNegatively modulating EIF5A2[98]
miR-133bCisplatinInhibiting GSTP1[99]
miR-130bCisplatinTargeting PTEN[100]
miR-935PaclitaxelRegulating SOX7[101]
Colorectal cancermiR-128-3pOxaliplatinNegatively modulating Bmi1 and MRP5[102]
miR-483-3pOxaliplatinIncreasing FAM171B[103]
miR-135bOxaliplatinRegulating FOXO1/Bim/Noxa axis[104]
miR-195-5p5-FUSuppressing Notch2/RBPJ signaling; Inhibiting GDPD5[105, 106]
miR-148aCisplatinModulating WNT10b and β-catenin pathway[107]
Ovarian cancermiR-142-5pCisplatinTargeting multiple anti-apoptotic genes including XIAP, BIRC3, BCL2, BCL2L2, MCL1[108]
miR-378a-3pCisplatinTargeting MAPK1/GRB2[109]
miR-363CisplatinModulating snail-induced EMT[110]
miR-139-5pCisplatinInactivation of MAPK pathway and RNF2[111]
miR-139CisplatinInhibition of ATP7A/B[112]
miR-34aCisplatinBlocking HDAC1[113]
miR-330-5pCisplatinDownregulating S100A7[114]
miR-149-5pCisplatinTargeting the core kinase components of the Hippo signaling pathway, MST1, SAV1; Inhibiting TEAD transcription[115]
miR-514CisplatinInteracting with ATP binding cassette subfamily[116]
miR-129PaclitaxelRegulating UCA1/miR-129/ABCB1 axis[117]
miR-874PaclitaxelRegulating miR-874/serine/ SIK2 axis[118]
miR-383-5pPaclitaxelRegulating miR-383-5p/TRIM27 axis[119]
miR-1246PaclitaxelRegulating miR-1246/Cav1/p-gp/M2-type macrophage axis[120]
GlioblastomamiR-151aTemozolomideSuppressing XRCC4-mediated DNA repair[121]
miR-519aTemozolomideTargeting STAT3/Bcl-2/Beclin-1 pathway[122]
miR-224-3pTemozolomideModulating HIF-1α/miR-224-3p/ATG5 axis[123]
miR-1238TemozolomideRegulating CAV1/EGFR pathway[124]
miR-501-3pCisplatinTargeting MYCN[125]
Gastric carcinomamiR-494DoxorubicinTargeting the 3’UTR region of PDE4D[126]
miR-6785-5p/ miR-642a-3p5-FURegulating FOXO4[127]
miR-17Cisplatin, 5-FUModulating DEDD[128]
miR-193a-3pCisplatinRegulating mitochondrial apoptosis pathway[129]
miR-155-5pPaclitaxelModulating GATA3 and TP53INP1[130]
Pancreatic carcinomamiR-200bGemcitabineReversing EMT[131]
miR-125a-3pGemcitabineReversing EMT[132]
miR-301GemcitabineRegulating cadherin 1 and inducing EMT[131]
OsteosarcomamiR-340CisplatinTargeting ZEB1[133]
miR-233CisplatinForming miR-233/Hsp70/JNK/JUN/ miR-233 feedback loop[134]
Papillary thyroid carcinomamiR-206EuthyroxBlocking p38 and JNK signaling pathway via targeting MAP 4 K3[135]